Drug updated on 4/17/2024
Dosage Form | Capsule (oral; lipase/protease/amylase [3,000 USP/9,500 USP/15,000 USP], [6,000 USP/19,000 USP/30,000 USP], [120,000 USP/38,000 USP/60, 000 USP], [24,000 USP, 76,000 USP, 120,000 USP], [36,000 USP, 114,000 USP, 180,000 USP]) |
Drug Class | Digestive enzymes |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
Summary
- Pancrelipase (Creon) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
- The information was derived from a single study which is a systematic review/meta-analysis.
- In terms of effectiveness, Creon improves PEI-related malabsorption and supports weight maintenance across several patient groups including those with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-surgical states.
- For patients suffering from chronic pancreatitis specifically, Creon also alleviates PEI-related symptoms.
- When compared to general treatment strategies for exocrine pancreatic insufficiency (PEI), Creon demonstrates superior safety and efficacy profiles according to the reviewed study.
- The proven benefits of Creon in various population types and subgroups are highlighted.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Creon (pancrelipase) Prescribing Information. | 2024 | AbbVie Inc. North Chicago, IL |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. | 2019 | World Journal of Gastroenterology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Evidence-based clinical practice guidelines for chronic pancreatitis 2021. | 2022 | Journal of Gastroenterology |